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Abstract
Background: HSVtk/ganciclovir (GCV) gene therapy has been extensively studied in tumors and
relies largely on the gene expression of HSVtk. Most studies, however, have failed to demonstrate
any significant benefit of a controlled gene expression strategy in cancer treatment. The Tet-On
system is commonly used to regulate gene expression following Dox induction. We have evaluated
the antitumor effect of HSVtk/ganciclovir gene therapy under Tet-On regulation by means of
adeno-associated virus-2 (AAV-2)-mediated HSVtk gene transfer with direct intratumoral injections
in mice bearing breast cancer tumors.
Methods: Recombinant adeno-associated virus-2 (rAAV) was constructed and transduced into
MCF-7 cell line. GCV treatment to the rAAV infected MCF-7 cells was performed by MTT assay
under the doxycycline (Dox) induction or without Dox induction at a vp (viral particle) number of
≥104 /cell. The virus was administered intratumorally to nude mice that had also received GCV
intraperitoneally. The antitumor effects were evaluated by measuring tumor regression and
histological analysis.
Results: We have demonstrated that GCV treatment to the infected MCF-7 cells under the Dox
induction was of more inhibited effects than those without Dox induction at ≥104 vp/cell. In ex vivo
experiments, tumor growth of BALB/C nude mice breast cancer was retarded after rAAV-2/
HSVtk/Tet-On was injected into the tumors under the Dox induction. Infiltrating cells were also
observed in tumors after Dox induction followed by GCV treatment and cells were profoundly
damaged. The expression of HSVtk gene in MCF-7 cells and BALB/C nude mice tumors was up-
regulated by Tet-On under Dox induction with reverse transcription-PCR (RT-PCR) analysis.
Conclusion: The antitumor effect of rAAV-mediated HSVtk/GCV gene therapy under the Dox
induction with direct intratumoral injections may be a useful treatment for breast cancer and other
solid tumors.
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Background
For enhancing gene therapeutic effects of breast cancer,
there are several approaches including the inhibition of
oncogene functioning [1], the rehabilitation of the tumor
suppressor genes [2], enhancement of the immune
response of tumor cells or immunological cells [3,4],
increase in the immunological tolerance at chemotherapy
of normal cells [5], suppression of tumor angiogenesis
[6], and the transformation of some apoptotic genes into
tumor cells [7], as well as suicide gene therapy [8]. The last
approach, which can offer the prospect of selectively
introducing genes into cancer cells, rendering them sus-
ceptible to specific antitumor drugs, is especially appeal-
ing for this bystander effect [9]. This is significant since the
high therapeutic index that can be achieved with a high
concentration of toxic drug will occur only at the tumor
site. The more widely used suicide gene system is the her-
pes simplex virus thymidine kinase/ganciclovir (HSVtK/
GCV). GCV, a kind of antiviral drug, can be phosphor-
ylated by HSVtK protein finally into triphosphates, which
are potent inhibitors of DNA polymerase, leading to the
disruption of cellular DNA synthesis and ultimately cell
death. These properties make the system attractive in can-
cer therapy [9,10].
The progress was made in increasing the product of thera-
peutic genes combined with suicide gene therapy using
either tumor cell-specific or tissue-specific promoters.
Both are capable of directing expression of a heterologous
gene in tumor cells [11-13]. However, only a few workers
have reported precise regulation of the HSVtk gene. Recent
studies have also shown that a specific dose of the thera-
peutic gene product is required for successful treatment of
certain disease, but excessive production of the gene prod-
uct may be toxic in some cases [14,15]. For better treat-
ment, it may be necessary to control the product of
therapeutic genes within a window of appropriate time
and dose. The Tet-On regulatable system can tightly regu-
late gene expression in response to induction and be
switched off when necessary, which is of value in gene
therapy [16]. The system is based on the interaction
between the tetracycline-responsive element (TRE), con-
sisting of seven copies of the prokaryotic tetracycline oper-
ator site (tetO) fused to a cytomegalovirus minimal
promoter region, and the reverse tetracycline-transactiva-
tor (rtTA), consisting of the prokaryotic tetracycline
repressor protein (TetR) fused to the activator domain of
the herpes simplex virus VP16 protein. In the presence of
tetracycline (tet) or its derivative Dox, rtTA binds TRE and
activates gene expression. Compared with several drug-
dependent regulatable systems, the Tet-On system shows
several superior characteristics for applications in
patients, including high induction, rapid reaction and
high specificity [17,18]. This system had been studied in
the context of numerous viral and non-viral vectors to reg-
ulate expression of various genes, and diseases needed
intermittent treatment [19].
For suicide gene therapy, the transfer of therapeutic genes
into the tumor cells and the maintenance of their expres-
sion in tumors require efficient vector systems. The adeno-
associated viral (AAV) is a promising gene transfer vector
for human gene therapy because of its unique combina-
tion of attractive properties. These include: (1) the effi-
ciency of in vivo gene transfer to a number of different cell
types, including skeletal muscle cells, hepatocytes, neu-
rons, and photoreceptors; (2) the ability to transduce
dividing and growth arrested cells; (3) the availability of
procedures for high-titre, helper virus-free preparation;
and (4) a lack of significant toxicity or immune response.
Furthermore, AAV-mediated gene delivery produces a
long-term gene expression following prenatal administra-
tion and after administration in adult tissues [20,21].
In our previous study, the pseudoviruses, pRevTRE/HSVtk
and pRevTet-On, in which the expression of suicide tk
gene is tightly controlled by Dox, were used to infect MCF-
7 cells or were directly delivered into the model of BALB/
c nude mice bearing human breast cancer. The findings
were that HSVtk gene expression was controlled by the
Dox-induced Tet-On system, and it is feasible for treating
human breast cancer [22,23]. However, TRE and rtTA
were respectively cloned into two vectors, which were
transferred into host cells at their appropriate ratios. There
is a latent danger in insertion mutation and activation of
oncogenes in human being using retroviral vector system
[24]. We explored the treatment of human breast cancer
by AAV-2 expressing HSVtk gene under the regulation of
Tet-On, the rAAV (rAAV-2/TRE/HSVtk/Tet-On) was con-
structed and transduced into MCF-7 cell line or BALB/c
nude mice. In order to test the antitumor effect with this
system, nude mice bearing breast cancer were treated with
GCV followed by rAAV intratumoral injection and consec-
utive induction by Dox. This antitumor treatment may
also offer a new approach and ideal model in human
breast cancer or other solid tumor gene therapy.
Methods
Cell line, cell culture and vectors
Packaging cell line 293 (ATCC # CRL-11268™), human
breast cancer cell line MCF-7 (ATCC # HTB-22™) and
mouse fibroblast cell line NIH 3T3 (ATCC # CRL-1658™)
originated from the American Type Culture Collection
(ATCC, Manassas, VA). Cells were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with
10 % of fetal bovine serum (FBS) plus 100 units of peni-
cillin per ml, and 0.1 mg of streptomycin per ml. The cells
were grown at 37°C in a humidified incubator with an
atmosphere of 5 % CO2. The AAV-2 Helper-Free system,
including the plasmids of pAAV-MCS, pAAV-RC, pAAV-BMC Cancer 2006, 6:66 http://www.biomedcentral.com/1471-2407/6/66
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Helper, came from Stratagene (La Jolla, California, USA).
The RevTet-On system, including the plasmids of pRev-
TRE and pRevTet-On, was supplied by Clontech (Palo,
Alto, CA).
The construction of pAAV/TRE/HSVtk/Tet-On
pRevTRE/HSVtk was constructed as previously described
[22]. In brief, Tet-On gene fragment was amplified by PCR
technique with primers Tet1/Tet2 (Tet1 5 ' -CTC TAT CGA
TGG ATC CGG CCA TTA GCC AT-3'; Tet2 5 ' -CTC TGT
TAA CTA CCC ACC GTA CTC GTC-3'; Cla I and Hpa I
restriction sites are shown in boldface) from the plasmid
pRevTet-On. The PCR product was recovered from agarose
gel and digested with Cla I and Hpa I. The recovered DNA
fragment was inserted into pRevTRE/HSVtk to produce
the recombinant plasmid pRevTRE/HSVtk/Tet-On. The
fusion DNA fragment of HSVtk and Tet-On was cut with
Xho I and Cla I and inserted into pAAV-MCS. The recom-
binant plasmid pAAV/TRE/HSVtk/Tet-On was constructed
followed by partial digestion of Not I and Cla I, filling the
3' end and self-ligation.
Preparation, purification and titre detection of rAAV
Packaging cells 293 were transfected by the method of
modified calcium phosphate co-precipitation with pAAV/
TRE/HSVtk/Tet-On, pAAV-RC and pAAV-Helper when the
cell monolayers were 50–60% confluent. The cells were
collected after 72 days of transfection, and resuspended in
cell lysis buffer (10 mM Tris-HCl, pH 8.5, 150 mM NaCl).
The cells were frozen and thawed 3 times in liquid nitro-
gen and 37°C respectively. The lysate was centrifuged at
4,000 g for 10 min and the supernatant was collected.
Solid NaCl and PEG-8000 were added in supernatant to
reach concentrations of 1 M and 10% (W/V) respectively,
and the mixture agitated to dissolve these components
whilst being incubated on ice for 1 h. After 9,000 g centrif-
ugation for 15 min, the pellet was mixed with 1.38 g/ml
of CsCl2 and centrifuged at 500,000 g for 24 h at 4°C to
isolate the AAV-2/TRE/HSVtk/Tet-On viral particles. Titre
detection was performed by dot blot hybridization for
purified rAAV. The physical titre of AAV-2/TRE/HSVtk/Tet-
On virus was 2.38 × 1011 viral particle/ml.
rAAV infections and MTT assay
MCF-7 cells were cultured at 2 × 103 cells per well in 96-
well plates. The experimental cultures were divided into 3
groups, to which 2 × 107, 2 × 108 and 2 × 109 vp of rAAV-
2/TRE/HSVtk/Tet-On were added per well, at 37°C for 8 h.
The ratio of viral particles and cells was as 104 vp/cell, 105
vp/cell, and 106 vp/cell. Twenty-four hours later, 1.0 µg/
ml Dox and 3.0µg/ml GCV (Sigma, St. Louis, MO) were
added to each well of group 1, 3.0 µg/ml GCV was added
to each well of group 2, and 1.0 µg/ml Dox was added to
each well of group 3. Cell viability was determined by the
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe nyltetrazolium
bromide (MTT, Sigma) assay after another 72 h incuba-
tion. The cells were incubated with 0.5% MTT for 4 h. The
medium was then removed and 100 µl of 0.04 M dime-
thyl sulfoxide solution added, followed by incubation at
37°C for a further 4 h. The absorbance of the reaction
product in solution at 570 nm was measured. The data
were expressed as mean ± S.D and used to draw growth
curves. To calculate the percentage of living cells, we
divided the cell number in the experimental wells by the
cell number in the control wells (no Dox or no GCV). The
growth curves were protracted by a manual count method.
After 48 h culture, viable cells were counted by the trypan
blue dye exclusion method. All experiments were per-
formed 4 times independently.
Detection of HSVtk gene expression
Expression of HSVtk gene in the infected MCF-7 cells and
tumor tissues of BALB/c nude mice was analyzed by RT-
PCR. 0.1 g of fresh tumor tissue with 1 ml of pre-cooled
TRIzol reagent (Invitrogen, La Jolla, CA) was homoge-
nized and total RNA was extracted according to instruc-
tion. RT-PCR was performed with nested primers TK3/TK4
(TK3: 5'-TGG AGC AGA AAA TGC CCA CG-3' TK4: 5'-TGC
TGC CCA TAA GGT ATC GC-3') (a DNA fragment of 420
bp). For internal control, β-actin (sense: 5'-TGA CGG TCA
GGT CAT CAC TAT CGG CAA TGA-3' and antisense: 5'-
TTG ATC TTC ATG GTG (AGC) TAG GAG CGA GGG CA-
3') were co-amplified with HSVtk (a DNA fragment of 260
bp). Before reverse transcription (RT), residual genomic
DNA was removed by treatment with RQ DNase
(Promega, Madison, WI). Total RNA (1.5 µg) was used to
synthesize cDNA in 20 µl of reaction mixture by standard
protocol with oligo(dT)15 as primer, and AMV reverse
transcriptase (Promega). PCR reactions were carried out
with 5 µl of RT products in 50 µl of reaction system using
Taq DNA polymerase. After an initial denaturation 94°C
for 5 min, 30 cycles of amplification were performed
under following condition: 94°C for 30 seconds, 56°C for
45 seconds, and 72°C for 40 seconds. PCR products were
run on 1.5 % agarose gel (containing 0.5 mg of ethidium
bromide per liter).
Establishment of human breast cancer models in BALB/c 
nude mice and GCV treatment
Female BALB/c nude mice, 4–5 week-old and weighing
20.0 ± 2.0 grams, came from the Laboratory Animal
Center of the Academy of Medical Sciences of China
(Shanghai, China). The mice were housed in vinyl cages
equipped with air filter lids, which were kept in laminar
airflow hoods and maintained under pathogen-limiting
conditions. All mice were cared for according to institu-
tional guidelines, and all food, water, caging, and bedding
were sterilized before use. All procedures were approved
by the National Animal Care and Use Committee in
China and the Laboratory Animal Center of the AcademyBMC Cancer 2006, 6:66 http://www.biomedcentral.com/1471-2407/6/66
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of Medical Sciences of Xiangya Medical College granted
approval for the experimental research on animals. BALB/
c nude mice were given a single priming dose of cyclo-
phosphamide (100 mg/kg body weight, subcutaneously
[s.c.]) 3 days prior to inoculation of cells to deplete the
natural killer cells of mice. MCF-7 cells were trypsinized,
washed with DMEM 3 times to remove enzyme, and har-
vested by centrifugation. Cell pellets were resuspended in
serum-free DMEM. After a short period of ether inhalation
anesthesia by nude mice, 2 × 107 cells in 0.2 ml of suspen-
sion were injected s.c. into the left flank regions to pro-
duce tumors. Tumor size was measured every 3 days with
vernier caliper. Thirty-two mice were randomly divided
into 4 groups: GCV + Dox (8 mice), GCV + rAAV (8 mice),
GCV + Dox + rAAV (8 mice), DMEM only (8 mice). When
tumors had reached 7–8 mm in diameter, intratumoral
injection of AAV-2/TRE/HSVtk/Tet-On (100 µl, 2 × 1011
vp/ml) or DMEM (mock group) was performed 4 times
(twice a week). Tumors in mice were induced by Dox (20
mg/kg) for 1 week prior to intraperitoneal administration
of GCV (100 mg/kg) twice daily for 14 days. The volumes
of tumor were calculated using the following formula:
volume V = L × W2 π/2, where L is the length and W is the
width of the tumor (in millimeters).
Histological analysis
Subcutaneous tumors were excised from BALB/c nude
mice with different treatments. Tumors were rinsed twice
in normal saline (NS) then fixed in 4% polyparaformalde-
hyde for 12 h, embedded in paraffin and sections were
stained with hematoxylin and eosin for light microscopic
observation.
Statistical analysis
Results are expressed as means ± standard deviation (S.D).
The statistical difference between the groups was deter-
mined by one-way analysis of variance test. The software
for statistics is SPSS (10.0 version). Differences among
groups were considered statistically different at P <0.05.
Results
Killing effect of HSVtk on MCF-7 cells under the induction 
of Dox
MCF-7 cells in 96-well plate were infected with 104 vp/
cell, 105 vp/cell and 106 vp/cell of AAV-2/TRE/HSVtk/Tet-
On respectively. After induction of 1.0 µg/ml Dox, the kill-
ing rate of rAAV+Dox+GCV with 104 vp/cell to MCF-7
reached 36%, as detected by using the MTT assay in the
presence of GCV (3.0 µg/ml). Increasing the viral titre to
106 vp/cell raised the cell death rate to 47% (Fig. 1).
Almost no difference was found between MCF-7 cells sur-
vival as rAAV infection reached a plateau when rAAV titres
ranged from 104 to 106vp/cell. Although CsCl2 density
gradient ultracentrifugation procedure allows for the
enrichment of pure and packaged AAV-2 vector particles,
it often produces vector preparations of variable quality,
and may lead to a loss of particle infectivity [21]. We also
indirect tested the transduction efficiency with pAAV-LacZ
according to the Stratagene protocol. In our experiment,
the efficiency of AAV infection to MCF-7 cells is 15–20%.
In all kinds of rAAV titres above, the cell death rate of
rAAV+Dox+GCV group was obviously higher than
rAAV+GCV group and rAAV+Dox group (P < 0.05).
GCV treatment for implanted human breast cancers in vivo
During the first 14 days of GCV treatment, tumor volume
in all groups increased at almost the same rate. However,
in the GCV + Dox + virus treated group, tumor growth rate
was retarded after 30 days compared with the control
groups (Fig. 2). In the controls, tumors grew continuously
up to 2 cm in diameter by the end of the 40th day when
the mice were killed. For tumors injected with rAAV, GCV
treatment after the induction of Dox resulted in suppres-
sion of all tumors by day 30 (Fig. 2). The suppression rate
of xenograft tumor growth reached up to 84%, and
showed a strong inhibitory effect on tumor growth in
vivo. These data suggested that HSVtk gene was expressed
Effects of rAAV/TRE/HSVtk/Tet-On on MCF-7 cells in the  presence of GCV followed by the induction of Dox Figure 1
Effects of rAAV/TRE/HSVtk/Tet-On on MCF-7 cells in 
the presence of GCV followed by the induction of 
Dox. MCF-7 cells were transduced with various doses of 
rAAV/TRE/HSVtk/Tet-On. Twenty-four hours after transduc-
tion, the rAAV+Dox+GCV group (blank bar) cells were 
exposed to 3.0 µg/ml GCV and 1.0 µg/ml Dox while the 
rAAV+Dox group (black bar) cells with 1.0 µg/ml Dox and 
the rAAV+GCV group (hatched bar) cells with 3.0 µg/ml 
GCV. After 3 days, the survival rate was calculated as 
described in Materials and Methods. Data showed that the 
survival rate of the rAAV+Dox+GCV group cells was differ-
ent from that of the other two groups cells. Values are 
expressed as means ± SD.BMC Cancer 2006, 6:66 http://www.biomedcentral.com/1471-2407/6/66
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in a regulated manner in implanted human breast cancer
infected intratumorally with rAAV.
Histological analysis of human breast cancer in BALB/c 
nude mice
BALB/c nude mice bearing human breast cancer with dif-
ferent treatments were given sodium pentobarbital (50
mg/kg, i.p.) anesthesia to excise the subcutaneous tumors.
In the hematoxylin and eosin stained sections, few accom-
panying infiltrating cells were seen in control groups. On
the other hand, remarkable levels of infiltration of lym-
phocytes were observed throughout the tumors that had
been injected with Dox followed by GCV treatment, and
breast cancer cells were severely damaged (Fig. 3).
HSVtk gene expression in tumor tissue and rAAV-infected 
MCF-7 cells
In order to evaluate the efficiency of gene transfer in vivo,
we used RT-PCR to detect the expression of HSVtk gene. A
420 bp fragment of HSVtk gene was observed, which was
consistent with predicted results (Fig. 4). We detected
high level of expression of HSVtk in tumor tissues of GCV
+ Dox+ rAAV treated group. The faintest band could be
detected in the rAAV+GCV group and no band in other
two groups (the DMEM group and the Dox+GCV group)
could be seen (Fig. 5). After induction of Dox, the HSVtk
expression level was enhanced by approximately fourfold
in tumors subjected to treatment with GCV and viruses.
This result was agreement with the growth of breast cancer
in mice. As expected, without HSVtk  expression, the
growth of parental MCF-7 cells was not affected by GCV
and tumors continued to grow until the mice were killed
because of large tumor loads. A similar result was
obtained in rAAV-infected MCF-7 cells.
Discussion
We constructed rAAV vector, which contained Tet-On reg-
ulatory sequences and the HSVtk  gene, in an effort to
develop a novel treatment for breast cancer and other
solid tumors. Our results demonstrate that this vector is
Tumor volume analysis after treatment in BALB/c nude mice Figure 2
Tumor volume analysis after treatment in BALB/c 
nude mice. Implanted tumors were generated by injecting 
MCF-7 cells in the flank in BALB/c nude mice. When subcuta-
neous tumors reached approximately 7–8 mm in diameter, 
rAAV/TRE/HSVtk/Tet-On virus (2 × 1011 particles/ml) or 
mock-infection (DMEM) were performed direct intratumor 
injection to human breast cancer model on day 0, followed 
by a second injection on day 7. GCV treatment (100 mg/kg) 
was started on day 0 and continued for another 14 days after 
induced by Dox for one week. Tumor size was measured 
every 3 days. Tumor volume values (mm3) are expressed as 
means ± SD. The tumors of the rAAV/tk/On+Dox+GCV 
group demonstrated significant tumor growth suppression 
after GCV treatment compared with mock (P < 0.05 on day 
30 after infection).
Tumor slices stained with hematoxylin and eosin Figure 3
Tumor slices stained with hematoxylin and eosin. 
Subcutaneous tumors were excised from BALB/c nude mice 
with different treatments under sodium pentobarbital (50 
mg/kg, i.p.) anesthesia. Tumors were rinsed twice in normal 
saline (NS) then fixed in 4% polyparaformaldehyde for 12 
hours, embedded in paraffin, sliced and sections stained with 
hematoxylin and eosin for light microscopic observation (× 
400 magnification). A: DMEM group; B: GCV+Dox group; C: 
GCV+Virus group; D: Dox+GCV+Virus group.BMC Cancer 2006, 6:66 http://www.biomedcentral.com/1471-2407/6/66
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capable of directing expression of the HSVtk gene in breast
cancer and results in suppression of tumor growth rate,
when delivered by direct intratumoral injection and
induced by appropriate Dox with conjunction of GCV.
Our results also suggest that direct intratumoral injection
is not only a simple and practical gene delivery method in
local cancer gene therapy, but that it also avoids systemic
toxicity [25]. All the cancerous nude mice survived longer
after the treatment, and toxicity of the treatment in mice
was acceptable.
In cancer gene therapy, viral vectors are the most efficient
means of delivering a corrective gene into human cells,
such as retroviral vectors and adenoviral vectors. How-
ever, the applications of retroviral vectors for gene therapy
face a number of challenges. Retroviral vectors has some
disadvantage of infection only dividing cells, randomly
integration of therapeutic gene, risk of insertional muta-
genesis and activation of oncogenes, which correlates with
tumor in human being [24]. The adenovirus vector is
potentially of a strong immunogenic character and has a
low transduction efficiency in solid tumor [26,27]. AAV
can integrate into the specific site of human chromosome
19 and is not pathogenic for human being, especially
without the risk of tumorigenesis. MCF-7 cells were highly
infected and expressed by recombinant AAV-2 vector in
study of Veldwijk [28]. Due to the small fragment of the
Tet-On  regulatory units, AAV-2 vector was allowed to
introduce the HSVtk gene although it possesses about 5
Kb capability. The tetracycline-responsive system is an
ideal system for tightly regulation gene expression medi-
ated by rAAV [29], because it is the tet responsive cassette
inducible unit whose activity is modified in response to
Dox. In rAAV vector we constructed, TRE and rtTA units of
Tet gene regulation system were inserted inversely each
other, to delete the downstream activity of the HSVtk gene
by rtTA gene promoter through antisense suppression and
subtraction.
Tumor growth in nude mice given our treatment was
inhibited but not eradicated. It is quite difficult to eradi-
cate the tumors treated by one kind of a single gene since
tumorigenesis and development is a complicated progress
involving multigenes [30]. In order to enhance the effici-
acy of the treatment, some approaches were adopted, such
as combination of two suicide genes or combination with
other therapies [30,31]. Suicide gene therapy in combina-
tion with other methods, such as adjuvant radiotherapy or
chemotherapy, may have some promising use in the clinic
because it does not produce any elevation of the toxic
side-effects in breast cancer treatment as it reaches drug
concentration high enough to cure local tumors [32,33].
For some long period and progressive diseases, such as
diabetes or cancer, the control of therapeutic genes expres-
sion is of great importance in this gene therapy. However,
intrinsic to lengthy gene therapy treatment is the need to
HSVtk gene expression level in implanted tumors of BALB/c  nude mice and detection by RT-PCR Figure 5
HSVtk gene expression level in implanted tumors of 
BALB/c nude mice and detection by RT-PCR. Total 
RNA was isolated from implanted tumors of nude 
mice.HSVtk gene expression level was detected by RT-PCR 
with the nested primers TK3/TK4 (a DNA fragment of 420 
bp). For internal control, β-actin was amplified together with 
HSVtk. The amplification product of HSVtk gene was 
observed in the Dox+GCV+virus group and the weak signal 
was detected in GCV+virus group. M: 100 bp Marker; 1: 
DMEM group; 2: GCV+Dox group; 3: GCV+virus group; 4: 
Dox+GCV+virus group.
MCF-7 cells were infected with 105 vp/cell of rAAV/TRE/ HSVtk/Tet-On Figure 4
MCF-7 cells were infected with 105 vp/cell of rAAV/
TRE/HSVtk/Tet-On. Twenty-four h after transduction, one 
group was exposed to 10 µg/ml of Dox and the other group 
without Dox administration. After 3 days, RNAs were 
extracted from the 2 groups and HSVtk gene expression was 
detected by RT-PCR with nested primers TK3/TK4 (a DNA 
fragment of 420 bp). For internal control, β-actin was co-
amplified with HSVtk. The amplification product of HSVtk 
gene was observed in Dox inducement group but not in 
without inducement group. M: 100 bp DNA ladder; 1:group 
without induction; 2:group inducted with 1 g/L DoxBMC Cancer 2006, 6:66 http://www.biomedcentral.com/1471-2407/6/66
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alter expression in response to disease progression,
growth and development of younger patients, or unto-
ward side-effects. Regulating gene expression by exoge-
nously administered drugs provides control over the level
of functional gene product. Regulation permits much
greater control over timing of gene expression and can
provide a baseline level of behavior or cellular function in
the presence of Dox. To have control over the time and
level of gene expression is essential for both the in vitro
and in vivo studies of gene function, especially for the
safety and efficacy of gene therapy.
The HSVtK gene expression in tumor cells of nude mice
was detected by RT-PCR and there was a faint HSVtK gene
expression without Dox induction, as shown in our data.
It may be due to leakage of the Tet-On regulatory system
[34], but this does not influence the efficiency of the treat-
ment as it has only lower suicide gene expression com-
pared with the experimental group. Sometimes the
therapeutic gene is still expressed when Dox does not exist
because there is a residual affinity between TRE and rtTA
units of the system. So many measures are taken using a
certain modified rtTA system which has shown promising
results in low basal expression in the absence of inducer,
high induced expression, high induction ratio, indiffer-
ence to endogenous cellular processes, low immunogenic-
ity of system components and safety of inducers [35-38].
We constructed rAAV vectors containing Tet-On system
and HSVtk gene to explore the effect of breast cancer treat-
ment. Our results show that the expression of HSVtk gene
was controlled by Tet-On system under the induction of
Dox, transduced by rAAV. The antitumor treatment
occurred with an acceptable toxicity level, and the treated
mice achieved long-term survival. The effectiveness of the
HSVtk/Tet-On/GCV system would provide an effective reg-
ulatory treatment strategy for breast cancer including
other solid tumors.
Conclusion
In conclusion, our data demonstrated that tumor growth
of BALB/C nude mice breast cancer was inhibited with
direct intratumoral injections of rAAV-2/HSVtk/Tet-On
under the Dox induction. The expression of HSVtk gene in
MCF-7 cells and BALB/C nude mice tumors was up-regu-
lated by Tet-On under Dox induction. Our studies suggest
that rAAV-mediated HSVtk/GCV gene therapy under the
Dox induction with direct intratumoral injections may be
a useful method in treatment for breast cancer and other
solid tumors.
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